CE Disclosures and Faculty Information

• TARGET AUDIENCE
  This activity has been designed to meet the educational needs of medical oncologists and other healthcare providers involved in the treatment of lung cancer.

  OVERVIEW OF ACTIVITY
  Lung cancer is a devastating disease that accounts for more cancer-related deaths among both men and women than any other tumor type. Historically, systemic therapeutic options have been limited, but recent advances in our understanding of cellular and tumor biology have resulted in the development of numerous therapies demonstrating benefit in lung cancer. Despite these advances, many clinical scenarios continue to exist in which multiple treatment options may be available but the optimal strategy is highly debatable and may depend on rapidly evolving clinical research data. This unique educational activity delivers highly applicable current clinical information delving into the personalized management of this challenging disease and provides clinicians with a concise, easy-to-understand resource to facilitate knowledge and application of optimal diagnostic and therapeutic approaches.

  LEARNING OBJECTIVES

  • Develop an evidence-based strategy for the initial staging and treatment of localized non-small cell lung cancer (NSCLC), exploring the role of adjuvant systemic therapy.
  • Apply the results of emerging clinical research to the recommendation of multimodality therapy for patients with Stage III NSCLC.
  • Compare and contrast the benefits and risks of combination chemobiologic and doublet and single-agent chemotherapy regimens when developing treatment plans for patients with advanced disease.
  • Use biomarkers, clinical characteristics and tumor histology to select individualized treatment approaches for patients with NSCLC in the adjuvant and metastatic settings.
  • Identify patients with metastatic NSCLC who may experience clinical benefit from the addition of continuation or switch maintenance biologic therapy and/or chemotherapy.
  • Differentiate among existing and emerging molecular-targeted therapies, and effectively integrate new compounds, when available, into individualized lung cancer treatment strategies.
  • Recognize the effect of NSCLC tumor-specific mutations on relative response or resistance to treatment with EGFR tyrosine kinase inhibitors, monoclonal antibodies and other emerging molecular-targeted agents.
  • Formulate management strategies for limited- or extensive-stage small cell lung cancer, considering the contributory roles of surgery, radiation therapy (local and prophylactic cranial irradiation) and chemotherapy.
  • Recall the design of ongoing clinical trials evaluating novel investigational agents in lung cancer, and counsel appropriately selected patients about availability and participation.

  ACCREDITATION STATEMENT
  Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

  
  CME credit is no longer available for this issue
  
  

  CREDIT DESIGNATION STATEMENT
  
  CME credit is no longer available for this issue
  
  

  HOW TO USE THIS CME ACTIVITY
  This CME activity consists of a video component. The participant should watch the video.

  
  CME credit is no longer available for this issue
  
  

  CONTENT VALIDATION AND DISCLOSURES
  Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess potential conflicts of interest with faculty, planners and managers of CME activities. Real or apparent conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

  FACULTY — The following faculty (and their spouses/partners) reported real or apparent conflicts of interest, which have been resolved through a conflict of interest resolution process:

  Jeffrey Bradley, MD
  S Lee Kling Professor of Radiation Oncology
  Alvin J Siteman Cancer Center
  Washington University School of Medicine
  St Louis, Missouri

  Paid Research: Varian Medical Systems Inc.

  Julie R Brahmer, MD
  Associate Professor of Oncology
  The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
  Baltimore, Maryland

  Advisory Committee: Bristol-Myers Squibb Company, Celgene Corporation, Genentech BioOncology, Lilly USA LLC, Merck; Paid Research: ArQule Inc, MedImmune Inc; Uncompensated Research: Bristol-Myers Squibb Company.

  Frank C Detterbeck, MD
  Professor and Chief, Section of Thoracic Surgery
  Yale University School of Medicine
  Director, Thoracic Oncology Program
  Yale Cancer Center
  Co-Director, Yale Lung Screening and Nodule Program
  New Haven, Connecticut

  Advisory Committee: Pfizer Inc; Speakers Bureau: Lilly USA LLC.

  Ramaswamy Govindan, MD
  Professor of Medicine
  Co-Director, Section of Medical Oncology
  Division of Oncology
  Washington University School of Medicine
  St Louis, Missouri

  Consulting Agreements: Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Covidien, Merck.

  John Heymach, MD, PhD
  Chief, Thoracic Medical Oncology
  Associate Professor of Thoracic/Head and Neck Medical Oncology
  The University of Texas MD Anderson Cancer Center
  Houston, Texas

  Advisory Committee: Bayer HealthCare Pharmaceuticals, Boehringer Ingelheim Pharmaceuticals Inc, Genentech BioOncology, GlaxoSmithKline, Pfizer Inc; Consulting Agreements: OSI Oncology; Contracted Research: Bayer HealthCare Pharmaceuticals, GlaxoSmithKline, ImClone Systems, a wholly owned subsidiary of Eli Lilly and Company, Lilly USA LLC, Pfizer Inc.

  Bruce E Johnson, MD
  Director, Lowe Center for Thoracic Oncology
  Dana-Farber Cancer Institute
  Professor of Medicine
  Harvard Medical School
  ASCO Translational Research Professor
  Boston, Massachusetts

  Advisory Committee: AstraZeneca Pharmaceuticals LP, Genentech BioOncology, Millennium: The Takeda Oncology Company, Pfizer Inc; Consulting Agreements: Chugai Pharmaceutical Co Ltd, Sanofi, Transgenomic Inc; Speakers Bureau: AstraZeneca Pharmaceuticals LP, Genentech BioOncology, Genzyme Corporation, Millennium: The Takeda Oncology Company; Stock Ownership: KEW Group LLC.

  Rogerio C Lilenbaum, MD
  Chief Medical Officer
  Smilow Cancer Hospital
  Professor of Medicine
  Yale University School of Medicine
  New Haven, Connecticut

  Consulting Agreement: Genentech BioOncology.

  Thomas J Lynch Jr, MD
  Director, Yale Cancer Center
  Physician-in-Chief, Smilow Cancer Hospital at Yale-New Haven
  Richard and Jonathan Sackler Professor of Internal Medicine
  New Haven, Connecticut

  Advisory Committee: Boehringer Ingelheim Pharmaceuticals Inc, Genentech BioOncology, Merck; Board of Directors: Infinity Pharmaceuticals Inc; Consulting Agreements: Boehringer Ingelheim Pharmaceuticals Inc, Genentech BioOncology, Merck; Other Remunerated Activities: Partners HealthCare.

  Jyoti D Patel, MD
  Associate Professor of Medicine
  Northwestern University
  Feinberg School of Medicine
  Division of Hematology/Oncology
  Chicago, Illinois

  Contracted Research: Lilly USA LLC.

  Alice Shaw, MD, PhD
  Assistant Professor of Medicine
  Harvard Medical School
  Center for Thoracic Cancers
  Massachusetts General Hospital
  Boston, Massachusetts

  Advisory Committee and Consulting Agreements: ARIAD Pharmaceuticals Inc, Chugai Pharmaceutical Co Ltd, Novartis Pharmaceuticals Corporation, Pfizer Inc.

  Mark A Socinski, MD
  Professor of Medicine and Thoracic Surgery
  Director, Lung Cancer Section
  Division of Hematology/Oncology
  Co-Director, UPMC Lung Cancer Center of Excellence
  Co-Director, Lung and Thoracic Malignancies Program
  University of Pittsburgh
  UPMC Cancer Pavilion
  Pittsburgh, Pennsylvania

  Contracted Research: Celgene Corporation, Genentech BioOncology, GlaxoSmithKline, Lilly USA LLC, Pfizer Inc, Synta Pharmaceuticals Corp; Data and Safety Monitoring Board: Abbott Laboratories; Speakers Bureau: Celgene Corporation, Genentech BioOncology, Lilly USA LLC.

  David R Spigel, MD
  Program Director
  Lung Cancer Research
  Sarah Cannon Research Institute
  Nashville, Tennessee

  Advisory Committee: Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Genentech BioOncology, Lilly USA LLC, Novartis Pharmaceuticals Corporation, Pfizer Inc, Sanofi.

  MODERATOR — Dr Love is president and CEO of Research To Practice, which receives funds in the form of educational grants to develop CME activities from the following commercial interests: AbbVie Inc, Algeta US, Allos Therapeutics, Amgen Inc, ArQule Inc, Astellas, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, Biodesix Inc, Biogen Idec, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Daiichi Sankyo Inc, Dendreon Corporation, Eisai Inc, EMD Serono Inc, Foundation Medicine Inc, Genentech BioOncology, Genomic Health Inc, Gilead Sciences Inc, Incyte Corporation, Lilly USA LLC, Medivation Inc, Merck, Millennium: The Takeda Oncology Company, Mundipharma International Limited, Novartis Pharmaceuticals Corporation, Onyx Pharmaceuticals Inc, Prometheus Laboratories Inc, Regeneron Pharmaceuticals, Sanofi, Seattle Genetics, Spectrum Pharmaceuticals Inc and Teva Oncology.

  RESEARCH TO PRACTICE STAFF AND EXTERNAL REVIEWERS — The scientific staff and reviewers for Research To Practice have no real or apparent conflicts of interest to disclose.

  This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

  This activity is supported by educational grants from Astellas, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Genentech BioOncology and Lilly USA LLC.

  Hardware/Software Requirements:
  A high-speed Internet connection 
  A monitor set to 1280 x 1024 pixels or more
  Internet Explorer 7 or later, Firefox 3.0 or later, Chrome, Safari 3.0 or later
  Adobe Flash Player 10.2 plug-in or later
  Adobe Acrobat Reader
  (Optional) Sound card and speakers for audio
  
  Last review date: May 2013
  Expiration date: May 2014